On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics

[1]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[2]  S. de Jong,et al.  Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. , 2010, Biochimica et Biophysica Acta.

[3]  S. Fulda,et al.  Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression , 2002, Oncogene.

[4]  A. Tolcher,et al.  Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Sporn,et al.  An Inducible Pathway for Degradation of FLIP Protein Sensitizes Tumor Cells to TRAIL-induced Apoptosis* , 2002, The Journal of Biological Chemistry.

[6]  S. Bruno,et al.  BH3‐only proteins: The death‐puppeteer's wires , 2009, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[7]  Shaomeng Wang,et al.  Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment , 2011, Molecular Cancer Therapeutics.

[8]  A. Oza,et al.  A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies , 2008, Clinical Cancer Research.

[9]  A. Thorburn,et al.  EGFR-targeted diphtheria toxin stimulates TRAIL killing of glioblastoma cells by depleting anti-apoptotic proteins , 2009, Journal of Neuro-Oncology.

[10]  A. Thorburn,et al.  Tumor-derived Mutations in the TRAIL Receptor DR5 Inhibit TRAIL Signaling through the DR4 Receptor by Competing for Ligand Binding* , 2007, Journal of Biological Chemistry.

[11]  H. Ford,et al.  Abrogation of the G2 cell cycle checkpoint associated with overexpression of HSIX1: a possible mechanism of breast carcinogenesis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[12]  D. Green,et al.  FLIP(L) induces caspase 8 activity in the absence of interdomain caspase 8 cleavage and alters substrate specificity. , 2011, The Biochemical journal.

[13]  P. Rougier,et al.  A phase Ib/II trial of AMG 655 and panitumumab (pmab) for the treatment (tx) of metastatic colorectal cancer (mCRC): Safety results. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Buchsbaum,et al.  Overcoming TRAIL resistance in ovarian carcinoma. , 2010, Gynecologic oncology.

[15]  A. Kraft,et al.  ABT-737 Induces Expression of the Death Receptor 5 and Sensitizes Human Cancer Cells to TRAIL-induced Apoptosis* , 2008, Journal of Biological Chemistry.

[16]  J. Tschopp,et al.  cFLIP regulation of lymphocyte activation and development , 2006, Nature Reviews Immunology.

[17]  D. Camidge,et al.  A randomized phase IItrial of mapatumumab, a TRAIL R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC , 2011 .

[18]  S. Pervaiz,et al.  TRAILing death in cancer. , 2010, Molecular aspects of medicine.

[19]  E. Henson,et al.  Increased expression of Mcl‐1 is responsible for the blockage of TRAIL‐induced apoptosis mediated by EGF/ErbB1 signaling pathway , 2003, Journal of cellular biochemistry.

[20]  R. Zeillinger,et al.  Contribution of Epigenetic Silencing of Tumor Necrosis Factor–Related Apoptosis Inducing Ligand Receptor 1 (DR4) to TRAIL Resistance and Ovarian Cancer , 2005, Molecular Cancer Research.

[21]  Peter Schow,et al.  Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax , 2002, Nature Medicine.

[22]  R. Eils,et al.  Model-based dissection of CD95 signaling dynamics reveals both a pro- and antiapoptotic role of c-FLIPL , 2010, The Journal of cell biology.

[23]  H. Ford,et al.  Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents. , 2011, Cancer research.

[24]  H. Ford,et al.  Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. , 2007, Cancer research.

[25]  R. Uzzo,et al.  Zinc chelation induces rapid depletion of the X-linked inhibitor of apoptosis and sensitizes prostate cancer cells to TRAIL-mediated apoptosis , 2008, Cell Death and Differentiation.

[26]  J. Posey,et al.  A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas , 2008 .

[27]  C. Fuchs,et al.  Safety and efficacy of AMG 655 plus modified FOLFOX6 (mFOLFOX6) and bevacizumab (B) for the first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  L. Amler,et al.  Development of Immunohistochemistry Assays to Assess GALNT14 and FUT3/6 in Clinical Trials of Dulanermin and Drozitumab , 2010, Clinical Cancer Research.

[29]  M. Smyth,et al.  Cutting Edge: TRAIL Deficiency Accelerates Hematological Malignancies1 , 2005, The Journal of Immunology.

[30]  T. Sayers,et al.  Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy , 2005, Cancer Immunology, Immunotherapy.

[31]  Hao Shen,et al.  Reduced Apoptosis and Ameliorated Listeriosis in TRAIL-Null Mice1 , 2004, The Journal of Immunology.

[32]  R. Herbst,et al.  A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors , 2010, Clinical Cancer Research.

[33]  Suzanne F. Jones,et al.  A phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI , 2007 .

[34]  H. Ford,et al.  Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[35]  W. El-Deiry,et al.  Direct Repression of FLIP Expression by c-myc Is a Major Determinant of TRAIL Sensitivity , 2004, Molecular and Cellular Biology.

[36]  J. Soria,et al.  Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. Spencer,et al.  TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy , 2001, Leukemia.

[38]  S. Sleijfer,et al.  Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study , 2009, Clinical Cancer Research.

[39]  V. Dixit,et al.  Apoptosis control by death and decoy receptors. , 1999, Current opinion in cell biology.

[40]  B. Bonavida,et al.  X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-bi , 2002, Molecular cancer therapeutics.

[41]  F. Stricher,et al.  Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants , 2010, Cell Death and Disease.

[42]  M. Smyth,et al.  Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice1 , 2002, The Journal of Immunology.

[43]  Guy S. Salvesen,et al.  Catalytic activity of the caspase-8-FLIPL complex inhibits RIPK3-dependent necrosis , 2011, Nature.

[44]  Jin Kuk Yang.  FLIP as an Anti-Cancer Therapeutic Target , 2008, Yonsei medical journal.

[45]  J. Houghton,et al.  Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  Andreas Untergasser,et al.  Preclinical Differentiation between Apparently Safe and Potentially Hepatotoxic Applications of TRAIL Either Alone or in Combination with Chemotherapeutic Drugs , 2006, Clinical Cancer Research.

[47]  T. Kwon,et al.  Quercetin sensitizes human hepatoma cells to TRAIL‐induced apoptosis via Sp1‐mediated DR5 up‐regulation and proteasome‐mediated c‐FLIPS down‐regulation , 2008, Journal of cellular biochemistry.

[48]  G. Cohen,et al.  Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1 , 2005, Cell Death and Differentiation.

[49]  H. Burris,et al.  A phase IB safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma , 2007 .

[50]  K. Kinzler,et al.  X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. , 2004, Cancer research.

[51]  Clemencia Pinilla,et al.  Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein , 2007, Molecular Cancer Therapeutics.

[52]  E. Smit,et al.  Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  H. Ford,et al.  TRAIL Receptor Signaling Regulation of Chemosensitivity In Vivo but Not In Vitro , 2011, PloS one.

[54]  D. Camidge,et al.  Apomab: An agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors , 2008 .

[55]  J. Vose,et al.  Results of a Phase 2 Trial of HGS-ETR1 (Agonistic Human Monoclonal Antibody to TRAIL Receptor 1) in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL). , 2005 .

[56]  R. Herbst,et al.  Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  K. Kelly,et al.  Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. , 2008, Lung cancer.

[58]  G. Cohen,et al.  TRAIL signals to apoptosis in CLL cells primarily through TRAIL R-1 whereas cross-linked agonistic TRAIL R-2 antibodies facilitate signalling via TRAIL R-2 , 2007 .

[59]  F. Zipp,et al.  Regulation of soluble and surface-bound TRAIL in human T cells, B cells, and monocytes. , 2003, Cytokine.

[60]  W. El-Deiry,et al.  Cell surface Death Receptor signaling in normal and cancer cells. , 2003, Seminars in cancer biology.

[61]  L. Andĕra,et al.  Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts , 2007, Molecular Cancer Therapeutics.

[62]  F. Civoli,et al.  A phase Ib study to evaluate the safety and efficacy of AMG 655 in combination with gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (PC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  W. El-Deiry,et al.  Deficient Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Death Receptor Transport to the Cell Surface in Human Colon Cancer Cells Selected for Resistance to TRAIL-induced Apoptosis* , 2004, Journal of Biological Chemistry.

[64]  P. Krammer,et al.  c-FLIPR, a New Regulator of Death Receptor-induced Apoptosis* , 2005, Journal of Biological Chemistry.

[65]  C. Karapetis,et al.  Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer (NSCLC). , 2010 .

[66]  G. Cohen,et al.  TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL‐R1 whereas cross‐linked agonistic TRAIL‐R2 antibodies facilitate signalling via TRAIL‐R2 , 2007, British journal of haematology.

[67]  G. Cavet,et al.  Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL , 2007, Nature Medicine.

[68]  A. Thorburn,et al.  Preclinical and Clinical Estimates of the Basal Apoptotic Rate of a Cancer Predict the Amount of Apoptosis Induced by Subsequent Proapoptotic Stimuli , 2010, Clinical Cancer Research.

[69]  W. El-Deiry,et al.  TRAIL receptor signaling and therapeutics , 2010, Expert opinion on therapeutic targets.

[70]  H. Wakelee,et al.  Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[71]  S. Marsters,et al.  Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family* , 1996, The Journal of Biological Chemistry.

[72]  Michael T. Fisher,et al.  Molecular determinants of response to TRAIL in killing of normal and cancer cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[73]  Ashkenazi,et al.  Lipopolysaccharide Induces Expression of APO2 Ligand/TRAIL in Human Monocytes and Macrophages , 2000, Scandinavian journal of immunology.

[74]  D. D. Billheimer,et al.  The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. , 2009, The Journal of clinical investigation.

[75]  T. Burns,et al.  Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. , 2001, The Journal of biological chemistry.

[76]  H. Ford,et al.  Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation. , 2008, Cancer research.

[77]  V. Shamovsky.  Caspase-8 activation , 2013 .

[78]  Christoph H Emmerich,et al.  TRAIL signalling: decisions between life and death. , 2007, The international journal of biochemistry & cell biology.

[79]  G. Gores,et al.  Mcl-1 Mediates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Human Cholangiocarcinoma Cells , 2004, Cancer Research.

[80]  S. Korsmeyer,et al.  Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. , 2003, Cancer research.

[81]  P. Krammer,et al.  The c-FLIP–NH2 terminus (p22-FLIP) induces NF-κB activation , 2006, The Journal of experimental medicine.

[82]  B. Sipos,et al.  TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma , 2006, Oncogene.

[83]  R. Herbst,et al.  First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors , 2007 .

[84]  S. S. Strom,et al.  Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions , 2001, Nature Medicine.

[85]  I. Jeremias,et al.  TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB , 2003, Oncogene.

[86]  F. Desmots,et al.  Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae. , 2005, Cancer research.

[87]  H. J. Um,et al.  Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. , 2009, Free radical biology & medicine.

[88]  T. Wilson,et al.  In vitro and in vivo characterisation of a novel c-FLIP-targeted antisense phosphorothioate oligonucleotide , 2010, Apoptosis.

[89]  R Montesano,et al.  Database of p53 gene somatic mutations in human tumors and cell lines. , 1994, Nucleic acids research.

[90]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[91]  S. Pervaiz,et al.  LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells via hydrogen peroxide-mediated mitogen-activated protein kinase activation and up-regulation of death receptors. , 2009, Cancer research.

[92]  M. von Mehren,et al.  Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  D. Lawrence,et al.  Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. , 2000, Immunity.

[94]  C. Boland,et al.  Who should be sent for genetic testing in hereditary colorectal cancer syndromes? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  Sanjeev Banerjee,et al.  Enhanced Anticancer Effect of the Combination of Cisplatin and TRAIL in Triple-Negative Breast Tumor Cells , 2011, Molecular Cancer Therapeutics.

[96]  F. Sinicrope,et al.  Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis Is Inhibited by Bcl-2 but Restored by the Small Molecule Bcl-2 Inhibitor, HA 14-1, in Human Colon Cancer Cells , 2004, Clinical Cancer Research.

[97]  T. Griffith,et al.  Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. , 2006, Cancer research.

[98]  L. Sedger,et al.  Characterization of the in vivo function of TNF‐α‐related apoptosis‐inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene‐deficient mice , 2002, European journal of immunology.

[99]  J. V. van Meerbeeck,et al.  Safety and efficacy of AMG 655 in combination with paclitaxel and carboplatin (PC) in patients with advanced non-small cell lung cancer (NSCLC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  S. Ray,et al.  Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor , 2005, Apoptosis.

[101]  R. Plummer,et al.  Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies , 2005 .

[102]  J. Wiezorek,et al.  Death Receptor Agonists as a Targeted Therapy for Cancer , 2010, Clinical Cancer Research.

[103]  D. Green,et al.  Inducible Dimerization and Inducible Cleavage Reveal a Requirement for Both Processes in Caspase-8 Activation* , 2010, The Journal of Biological Chemistry.

[104]  L. Lenz,et al.  TRAIL-R as a negative regulator of innate immune cell responses. , 2004, Immunity.

[105]  H. Hurwitz,et al.  Phase Ib study of recombinant human Apo2L/TRAIL plus irinotecan and cetuximab or FOLFIRI in metastatic colorectal cancer (mCRC) patients (pts): Preliminary results. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  K. Bhalla,et al.  Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. , 2001, Cancer research.

[107]  C A Smith,et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.

[108]  Yidong Chen,et al.  MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers , 2010, Oncogene.

[109]  S. Strom,et al.  Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand , 2000, Nature Medicine.